Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

PARP-1 involvement in growth inhibitory effects of temozolomide and topotecan in p53 wild-type (D54) and p53 mutated (U251) glioblastoma cells

S. Pepe, G. Cimmino, D. Melisi, G. Laus, S. Di Meglio, G. Tortora, A. Bianco, P. Quesada

Med Sci Monit 2003; 9(1): 56-0 :: ID: 15121

Abstract

Malignant gliomas occur more frequently than other types of primary central nervous system tumors. Among the chemotherapic agents, temozolomide (TZM) and topotecan (TPT) represent important new drugs active in such neoplastic diseaseas. Moreover, preclinical studies have evaluated the combination of these agents and inhibitors of the DNA repair enzymes [1].In the present study we investigated cell growth inhibition and cell cycle perturbation induced by TPT or TZM treatment in the presence of the specific PARP-1 inhibitor NU 1025 in two gliobastoma cell lines, the D54 (p53 wt) and the U251 (p53 mut). Agar-colony-forming assay showed a different sensitivity of both cell lines to TPT or TZM. Moreover, combined treatment with TZM and non cytotoxic concentration of NU1025 induced a 25% increase of growth inhibition in D54 and U251; the same additive effect was observed mainly in U251 for TPT plus NU1025 treatment. DNA-flow cytometry showed that TZM and TPT induce an accumulation of cells in G2M phase of cell cycle and that PARP-1 inhibitor addition doubled G2M block in TZM treated cells.The characterization of the poly(ADP-ribosyl)ation system in both glioblastoma cell lines is in progress and particular attention will be made to define PARP-1 involvement in p53 dependent and independent signal transduction system.References: 1.Friedman SH, Kerby T, Calvert H: Clin Cancer Res, 2000; 6: 2585-2597

Keywords: PARP-1, temozolomide, Topotecan, p53, Cells

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

26 Feb 2024 : Clinical Research  

Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...

Med Sci Monit In Press; DOI: 10.12659/MSM.942509  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750